Key regions: United Kingdom, Brazil, Europe, France, Canada
Malta, an archipelago in the Mediterranean Sea, has been experiencing a steady growth in its healthcare industry. Among the drugs that have been gaining popularity in the country are Anti-Fibrinolytic Drugs, which are used to treat bleeding disorders.
Customer preferences: The Maltese population has been showing an increasing preference for Anti-Fibrinolytic Drugs due to the rise in the number of patients suffering from bleeding disorders. The country has a high prevalence of hemophilia, a genetic disorder that affects the blood's ability to clot. Patients with hemophilia require regular infusions of Anti-Fibrinolytic Drugs to prevent bleeding episodes.
Trends in the market: The Anti-Fibrinolytic Drugs market in Malta has been growing due to the increase in the number of patients suffering from bleeding disorders. The market has been witnessing a shift towards the use of newer drugs that have fewer side effects and are more effective in preventing bleeding episodes. The trend towards the use of newer drugs has been driven by the increasing awareness among patients and healthcare providers about the benefits of these drugs.
Local special circumstances: Malta has a small population of just over 500,000 people, which means that the market for Anti-Fibrinolytic Drugs is relatively small. However, the country's high prevalence of hemophilia has created a demand for these drugs. The Maltese government provides free healthcare to its citizens, which means that patients with bleeding disorders can receive treatment at no cost. This has helped to increase the demand for Anti-Fibrinolytic Drugs in the country.
Underlying macroeconomic factors: The Maltese economy has been growing steadily in recent years, driven by the country's strong tourism industry and its status as a hub for financial services. The growth of the economy has led to an increase in healthcare spending, which has helped to drive the growth of the Anti-Fibrinolytic Drugs market. The country's membership in the European Union has also helped to boost the healthcare industry by providing access to new drugs and medical technologies.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
